GSK

Business Context and Reporting Period

This Form 6-K filing by GSK plc covers the month of March 2023, with the report dated March 13, 2023. The document serves as a transaction notification disclosing insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of specific share transactions.

Material Changes

No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by executives and their associates, which are standard compliance notifications rather than indicators of material corporate events.

Guidance, Outlook, and Risks

The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a factual record of share acquisitions executed on March 9, 2023.

Important Facts for Investors

• Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, involving both partnership and matching shares.
• Participants: Transactions were executed by eight individuals, including the CEO (Ms E Walmsley), SVPs, Presidents, and the Company Secretary, as well as one PCA.
• Uniform Pricing: All shares were acquired at a uniform price of £14.2259 per share.
• Volume: Individual transaction volumes were small, ranging from 16 to 18 shares per person, totaling 134 shares across all reported transactions.
• Scope Limitation: This filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for financial performance data.